Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors: Clinical utility and possibilities of overcoming resistance

14 Oct 2017

Abstract excerpt

PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair pathway, namely BRCA1/2 mutations. Given the limited therapeutic options for recurrent ovarian cancer patients there has been a significant effort to develop novel therapies to exploit DNA repair deficiencies. In 2005 and 2006, inhibiting PARP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29037806
DOI: 10.1016/j.ygyno.2017.10.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors: Clinical utility and possibilities of overcoming resistancePMID 29037806Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategiesSemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.